Skip to main content

Teva Pharmaceutical Industries



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.4%. By the end of trading, Teva Pharmaceutical Industries fell 33 cents (-0.8%) to $40.89 on light volume. Throughout the day, 1.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.8 million shares. The stock ranged in price between $40.45-$41.29 after having opened the day at $40.47 as compared to the previous trading day's close of $41.22. Other company's within the Drugs industry that declined today were:




), down 23%,

Savient Pharmaceuticals



), down 12.2%,

K-V Pharmaceutical Company



), down 10.7%, and

Arena Pharmaceuticals



), down 10.4%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $36 billion and is part of the

health care

sector. The company has a P/E ratio of 13.4, above the average drugs industry P/E ratio of 12.8 and below the S&P 500 P/E ratio of 17.7. Shares are up 2.1% year to date as of the close of trading on Monday. Currently there are 20 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself.

On the positive front,




), up 9.3%,

China Pharma



), up 9.1%,

Impax Laboratories



), up 8.3%, and




), up 6.9%, were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech